Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.RSV.preF (Janssen Pharmaceutical)
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.RSV.preF is an investigational vaccine candidate developed by Janssen (a Johnson & Johnson company) for the prevention of Respiratory Syncytial Virus (RSV) infection and associated lower respiratory tract disease (LRTD). The vaccine utilizes a unique dual-component approach within a single injection, combining an adenovirus serotype 26 (Ad26) viral vector that expresses the RSV fusion (F) protein stabilized in its prefusion conformation with a recombinant RSV prefusion F protein subunit. This design is intended to stimulate both potent cellular (T-cell) and humoral (antibody) immune responses, mimicking a prime-boost strategy. The vaccine demonstrated approximately 80% efficacy against RSV-mediated LRTD in older adults during Phase 2b (CYPRESS) and Phase 3 trials. However, in March 2023, Johnson & Johnson announced the discontinuation of its RSV vaccine program to prioritize other assets in its pipeline.
- Other names
- Ad26/protein preF RSV vaccineadenovirus serotype 26 RSV prefusion F protein vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on Ad26.RSV.preF (Janssen Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.RSV.preF (Janssen Pharmaceutical).